The government’s recommendation for approval for the vaccine was issued on Tuesday (23 Feb), the first of three expert panels in South Korea to study the vaccine COVID-19 developed by Pfizer and BioNTech.
On Friday, on the same day that Korea starts its immunization campaign, the national pharmaceutical panel is preparing to make its recommendation.
But before it determines whether to grant consent, the government will wait for a third panel, which has not said when to come to a conclusion.
A vaccine from AstraZeneca and Oxford University will be inoculated in high-risk individuals who are prioritized at the beginning of the vaccination program.
One day later, however, South Korea will use 117,000 doses of Pfizer BioNTech vaccine supplied with COVAX, the international sharing program for coronavirus vaccines, bypassing the need for final approval from the government.
Around 55,000 people will receive the Pfizer-Bio NTech vaccine on Saturday at COVID-19 treatment facilities.
The Pfizer-BioNTech vaccine was first announced by the panel that people aged 16 or over should be administered, taking into account its global test results and approval in many other countries.
Pfizer pledged a doubling of its US vaccine supply by mid-March, increasing its global production targets to at least 2 billion doses by 2021.
357 new cases of coronavirus were registered in South Korea on Monday. The estimated number of infections is now 87,681, with 1.573 deaths.